echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: Trajectory comparison of key clinical characteristics of dementia patients diagnosed at autopsy: Dementia with Lewy bodies (DLB) patients deteriorate faster than Alzheimer's disease (AD) patients!

    Neurology: Trajectory comparison of key clinical characteristics of dementia patients diagnosed at autopsy: Dementia with Lewy bodies (DLB) patients deteriorate faster than Alzheimer's disease (AD) patients!

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alzheimer's disease (AD), the leading cause of dementia, is clinically characterized by progressive memory and functional decline, pathologically characterized by neurofibrillary tau tangles originating in the medial temporal lobe and amyloidosis originating in the neocortex plaque


    Alzheimer's disease (AD), the leading cause of dementia, is clinically characterized by progressive memory and functional decline, pathologically characterized by neurofibrillary tau tangles originating in the medial temporal lobe and amyloidosis originating in the neocortex plaque


    The current literature on AD clinical symptom trajectories shows inconsistent results compared with DLB


    In contrast to clinical diagnoses, studies based on pathologically confirmed diagnoses provide an objective gold standard for diseases and thus require a full understanding of the disease trajectories of these diseases


    In addition to cognitive impairment, loss of function, especially the ability to perform self-care tasks, is a distinct feature of these degenerative disorders and is inevitably associated with a patient's dependence on family members or formal caregivers


    The current retrospective longitudinal study included 62 patients with autopsy-confirmed AD alone (n=34), mixed AD+DLB (AD+DLB, n=17), and DLb alone (n=11)


    The current retrospective longitudinal study included 62 patients with autopsy-confirmed AD alone (n=34), mixed AD+DLB (AD+DLB, n=17), and DLb alone (n=11)


    • During a mean follow-up period of 5.


      In this longitudinal study, it was found that among people with dementia, those with dementia with Lewy bodies experienced a faster rate of cognitive and functional decline than those with Alzheimer's disease alone


      Source: Gu Y, Kociolek A, Fernandez KK, et al.
      Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes [published online ahead of print, 2022 Apr 4].
      Neurology.
      2022;10.
      1212 /WNL.
      0000000000200259.
      doi:10.
      1212/WNL.
      0000000000200259 Gu Y, Kociolek A, Fernandez KK, et al.
      Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes [published online ahead of print, 2022 Apr 4].
      Neurology.
      2022; 10.
      1212/WNL.
      0000000000200259.
      doi: 10.
      1212/WNL.
      0000000000200259

      Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.